Pfizer stock

PFE · NYSE · USD

$28.89Change from previous close: +0.21%Absolute change: +$0.06

Close · November 13, 2026

Price history

+12.02% over the period

1 year: from $25.79 (November 13, 2025) to $28.89 (November 13, 2026), +12.02%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$28.89
October 30, 2026$30.52
September 30, 2026$28.52
August 31, 2026$28.46
July 31, 2026$25.01
June 30, 2026$24.08
May 29, 2026$26.18
April 30, 2026$26.70
March 31, 2026$28.08
February 27, 2026$27.65
January 30, 2026$26.44
December 31, 2025$24.90
November 28, 2025$25.74
November 13, 2025$25.79

At a glance

  • The company

    Discovers, develops, manufactures and sells biopharmaceutical products for internal medicine, inflammation, immunology, rare diseases, anti-infectives and oncology

  • Latest results

    Quarter to September 30, 2026 · EPS $0.87 (estimate $0.73)

TickerLandia's take on Pfizer

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$23.62
52-wk high$31.44

−8.11% from the 52-week high

Analysts · 28 analysts

Average target$30.22+4.61% vs. price

Buy 9 · Hold 17 · Sell 2 · Buy

TickerLandia Fingerprint: Pfizer

Compared with similar companies: very high dividend, very low growth, and very low risk.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Pfizer is priced as in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Pfizer's P/E today is 21.2, in line with the median of its last 10 fiscal years (18.6; between 9.37 and 77.8 from 2016 to 2025). Pfizer's P/E (trailing 12 months): 41.3, in line with the median of a group of 10 similar companies (42.3).

P/E compared with its history

Compared with 10 similar companies

Pfizer's metrics compared with similar companies
MetricPfizerPosition in the groupBand
P/E (trailing 12 months)41.3Middle
Forward P/E9.80Low
Operating margin29.1%Middle
ROE4.5%Low
Debt/equity0.71Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Pfizer. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$16.58B

Latest quarter · Q3 2026

Net income

$3.24B

Latest quarter · Q3 2026

Quarterly net margin

19.6%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$164.67B
P/E
41.3
EPS
$0.70
Volume
21.45M
Daily trading
€951.54M
Dividend yield
5.95%
Last ex-dividend on November 6, 2026

How Pfizer is changing

All results
  • Revenue grew 8.5% a year on average over the last 5 years

  • Operating margin fell from 39.4% to 30.6%

  • Profits turn into cash: free cash flow equal to 132% of net income

Returns

Pfizer returns with dividends

$1,000 invested in Pfizer 5 years ago, on November 15, 2021, would be worth $763 today with dividends reinvested: −23.69% in total, −5.27% per year. On price alone it would be $582 (−41.81%).

PeriodPfizerS&P 500$1,000 becomes
1 month+1.83%−3.12%$1,018
6 months+11.29%+1.58%$1,113
Year to date+16.02%+10.46%$1,160
1 year+19.56%+12.23%$1,196
3 years+21.08%+71.41%$1,211
5 years−23.69%+61.48%$763
10 years+49.01%+249.40%$1,490

Over the last 6 months it has done better than 38% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Pfizer: technical analysis

Pfizer is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 52.8% below its highest close since January 2, 1990 ($61.25, December 16, 2021).

Trend
Upward
RSI (14 sessions)
45
Between 30 and 70
vs 200-session average
+7.06%

Support and resistance

Price areas where Pfizer has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$29.21+1.12%2 touches, last on October 28, 2026
  2. Last price$28.89
  3. Support$28.75−0.50%3 touches, last on November 6, 2026
  4. Support$27.80−3.77%6 touches, last on August 31, 2026
  5. Support$27.19−5.90%2 touches, last on October 5, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.27
Volatility (60 sessions, annualised)
20.2%
Largest fall in the last year
−17.09%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Pfizer: seasonality

Average monthly price change over 37 years

−0.0%Jan−1.4%Feb+1.3%Mar+1.4%Apr+1.1%May−0.6%Jun+1.6%Jul−0.1%Aug+0.4%Sep+2.1%Oct+2.4%Nov+1.0%Dec

Over the last 37 years, the strongest month for Pfizer has been November: +2.42% on average, positive in 25 years out of 36. The weakest has been February: −1.43% on average, positive in 15 years out of 37.

Show chart data
MonthAverageMedianPositive years
January−0.03%+0.14%18 of 36
February−1.43%−1.26%15 of 37
March+1.28%+1.20%22 of 37
April+1.43%+1.10%21 of 37
May+1.14%+0.88%20 of 37
June−0.61%−0.98%17 of 37
July+1.62%+1.04%19 of 37
August−0.08%−0.54%18 of 37
September+0.37%−0.24%18 of 37
October+2.13%+1.70%25 of 37
November+2.42%+3.23%25 of 36
December+1.05%+0.06%18 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Pfizer and its competitors

Biopharmaceutical products form the core of the business, organized into three segments: Biopharma, PC1 and Pfizer Ignite. Internal medicine includes Eliquis for cardiovascular metabolic diseases, Nurtec ODT/Vydura and Zavzpret for migraine, the Prevnar family and Abrysvo among vaccines, and Paxlovid for COVID-19. Inflammation and immunology products include Xeljanz, Enbrel and Cibinqo, while rare disease treatments cover amyloidosis, hemophilia and endocrine diseases with the Vyndaqel family, Genotropin and BeneFIX.

Headquarters
New York, United States
Employees
75,000
Founded
1849
Chief executive
Albert Bourla
Pfizer and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
PfizerPFE$164.67B29.1%41.3+11.29%
Gilead SciencesGILD$208.48B38.2%—+26.33%
Bristol-Myers SquibbBMY$129.66B32.4%14.1+12.48%
AmgenAMGN$251.89B34.1%27.0+38.41%
MerckMRK$364.26B35.2%147.8+30.24%
AbbVieABBV$521.5B36.6%50.6+41.50%

Same industry or related industries, similar size. Compare Pfizer with its competitors · Full profile